DE60113299D1 - Neue vakzinformulierung aus dna-vakzine-inaktiviertem virus - Google Patents

Neue vakzinformulierung aus dna-vakzine-inaktiviertem virus

Info

Publication number
DE60113299D1
DE60113299D1 DE60113299T DE60113299T DE60113299D1 DE 60113299 D1 DE60113299 D1 DE 60113299D1 DE 60113299 T DE60113299 T DE 60113299T DE 60113299 T DE60113299 T DE 60113299T DE 60113299 D1 DE60113299 D1 DE 60113299D1
Authority
DE
Germany
Prior art keywords
virus
vaccine
formulation
dna
inactived
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60113299T
Other languages
English (en)
Other versions
DE60113299T2 (de
Inventor
Narasimhan Rangarajan Pundi
Alwar Srinivasan Villuppanoor
Biswas Subhabrata
Sreenivasa Reddy Guddeti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indian Institute of Science IISC
Indian Immunologicals Ltd
Original Assignee
Indian Institute of Science IISC
Indian Immunologicals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indian Institute of Science IISC, Indian Immunologicals Ltd filed Critical Indian Institute of Science IISC
Application granted granted Critical
Publication of DE60113299D1 publication Critical patent/DE60113299D1/de
Publication of DE60113299T2 publication Critical patent/DE60113299T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20111—Lyssavirus, e.g. rabies virus
    • C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60113299T 2001-02-15 2001-02-15 Neue vakzinformulierung aus dna-vakzine-inaktiviertem virus Expired - Lifetime DE60113299T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2001/000018 WO2002078732A1 (en) 2001-02-15 2001-02-15 A noval vaccine formulation consisting of dna vaccine inactivated virus

Publications (2)

Publication Number Publication Date
DE60113299D1 true DE60113299D1 (de) 2005-10-13
DE60113299T2 DE60113299T2 (de) 2006-06-08

Family

ID=11076305

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60113299T Expired - Lifetime DE60113299T2 (de) 2001-02-15 2001-02-15 Neue vakzinformulierung aus dna-vakzine-inaktiviertem virus

Country Status (7)

Country Link
US (1) US20040096462A1 (de)
EP (1) EP1365799B1 (de)
CN (1) CN1245217C (de)
AT (1) ATE303821T1 (de)
CA (1) CA2431938A1 (de)
DE (1) DE60113299T2 (de)
WO (1) WO2002078732A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1593392B1 (de) * 2004-05-07 2011-09-28 Novartis Vaccines and Diagnostics GmbH Tollwut-Impfstoff
EP1844142B1 (de) 2005-01-20 2015-08-12 Nature Technology Corporation Vektoren und verfahren zur genetischen immunisierung
US20060275776A1 (en) * 2005-06-01 2006-12-07 Angelika Banzhoff Rabies vaccine
CN101095950B (zh) * 2006-06-30 2011-01-26 辽宁成大生物股份有限公司 一种稳定的人用狂犬病疫苗冻干制剂及其制备
WO2008153733A2 (en) 2007-05-29 2008-12-18 Nature Technology Corporation Vectors and methods for genetic immunization
CN101768206B (zh) * 2008-12-31 2013-05-15 华北制药集团新药研究开发有限责任公司 一种重组人血清白蛋白的纯化方法及其应用
CN109196104B (zh) * 2016-04-11 2023-01-31 生源霸科乌拉圭有限公司 用于病毒性疾病的广效型疫苗

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5348741A (en) * 1987-02-03 1994-09-20 The United States Of America As Represented By The Department Of Health And Human Services Vector for recombinant poxvirus expressing rabies virus glycoprotein
AU3866389A (en) * 1988-07-01 1990-01-23 Salk Institute Biotechnology/Industrial Associates, Inc., The Production of rabies glycoprotein g and composition therefor
DE69632235T2 (de) * 1995-10-18 2004-08-26 Akzo Nobel N.V. Newcastle-Krankheitsvirus-Kombinationsimpfstoff
AU711915B2 (en) * 1995-12-21 1999-10-21 Dimminaco Ag Plasmid vaccine against pseudorabies virus
FR2751227B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives

Also Published As

Publication number Publication date
ATE303821T1 (de) 2005-09-15
EP1365799A1 (de) 2003-12-03
CN1494432A (zh) 2004-05-05
WO2002078732A1 (en) 2002-10-10
US20040096462A1 (en) 2004-05-20
CA2431938A1 (en) 2002-10-10
WO2002078732A9 (en) 2005-07-07
CN1245217C (zh) 2006-03-15
DE60113299T2 (de) 2006-06-08
EP1365799B1 (de) 2005-09-07

Similar Documents

Publication Publication Date Title
WO2020193688A3 (en) Immunogenic compositions and vaccines comprising african swine fever virus peptides and proteins and uses thereof
MX2023000411A (es) Vacuna combinada de sars-cov-2 e influenza.
DK1090033T4 (da) Partikler af HCV-kappeproteiner: Anvendelse til vaccination
WO2004030608A3 (en) Nanoemulsion vaccines
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
DK1326636T3 (da) Vaccinesammensætning
DK1294893T3 (da) Modifikation af hepatitis B-kerneantigen
AP2002002685A0 (en) Use of flavivirus for the expression of protein epitpoes and development of new live attenuated vaccine virus to immune against flavivirus and other infectious agents
EP1594536A4 (de) Adjuvante influenza-vakzine
MX2009000650A (es) Vacunas para malaria.
WO2001089559A3 (en) Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
BR0312173A (pt) Mólecula de cdna, molécula e sequência de cdna recombinante, vetor, processo de preparação de partìculas de vìrus do sarampo infeccioso, composição imunogênica, composição de vacina e vìrus mononegaviral recombinante
BRPI0113155C1 (pt) métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b
DK1409692T3 (da) Nye peptider afledt af G-proteinet fra RSV, og anvendelse heraf i en vaccine
BR0312474A (pt) Partìcula viral adjuvante
DK1949913T3 (da) Immunstimulatorisk kombination til profylakserne og behandlingen af hepatitis C
DK1545605T3 (da) Komposition til vaccination
DE60113299D1 (de) Neue vakzinformulierung aus dna-vakzine-inaktiviertem virus
ATE456958T1 (de) Mannose als adjuvant für intranasale vakzine
WO2005011571A3 (en) Hepatitis virus core proteins as vaccine platforms and methods of use thereof
CY1109206T1 (el) gM- ΑΡΝΗΤΙΚΟΙ EHV-ΜΕΤΑΛΛΑΚΤΕΣ ΧΩΡΙΣ ΕΤΕΡΟΛΟΓΑ ΣΤΟΙΧΕΙΑ
EA200301151A1 (ru) Вакцина против натуральной оспы
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine
DK1423525T3 (da) Rekombinant MVA, der kan eksprimere HCV-strukturantigener
ES2155510T3 (es) Vacuna mejorada para la inmunizacion contra infecciones por el virus tbe y procedimiento para su preparacion.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee
8370 Indication related to discontinuation of the patent is to be deleted